Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.
Publication
, Journal Article
DiNardo, CD; Stein, EM; Pigneux, A; Altman, JK; Collins, R; Erba, HP; Watts, JM; Uy, GL; Winkler, T; Wang, H; Choe, S; Liu, H; Wu, B ...
Published in: Leukemia
November 2021
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Leukemia
DOI
EISSN
1476-5551
Publication Date
November 2021
Volume
35
Issue
11
Start / End Page
3278 / 3281
Location
England
Related Subject Headings
- Survival Rate
- Pyridines
- Prognosis
- Neoplasm Recurrence, Local
- Mutation
- Middle Aged
- Male
- Leukemia, Myeloid, Acute
- Isocitrate Dehydrogenase
- Immunology
Citation
APA
Chicago
ICMJE
MLA
NLM
DiNardo, C. D., Stein, E. M., Pigneux, A., Altman, J. K., Collins, R., Erba, H. P., … de Botton, S. (2021). Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. Leukemia, 35(11), 3278–3281. https://doi.org/10.1038/s41375-021-01229-x
DiNardo, Courtney D., Eytan M. Stein, Arnaud Pigneux, Jessica K. Altman, Robert Collins, Harry P. Erba, Justin M. Watts, et al. “Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.” Leukemia 35, no. 11 (November 2021): 3278–81. https://doi.org/10.1038/s41375-021-01229-x.
DiNardo CD, Stein EM, Pigneux A, Altman JK, Collins R, Erba HP, et al. Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. Leukemia. 2021 Nov;35(11):3278–81.
DiNardo, Courtney D., et al. “Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.” Leukemia, vol. 35, no. 11, Nov. 2021, pp. 3278–81. Pubmed, doi:10.1038/s41375-021-01229-x.
DiNardo CD, Stein EM, Pigneux A, Altman JK, Collins R, Erba HP, Watts JM, Uy GL, Winkler T, Wang H, Choe S, Liu H, Wu B, Kapsalis SM, Roboz GJ, de Botton S. Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. Leukemia. 2021 Nov;35(11):3278–3281.
Published In
Leukemia
DOI
EISSN
1476-5551
Publication Date
November 2021
Volume
35
Issue
11
Start / End Page
3278 / 3281
Location
England
Related Subject Headings
- Survival Rate
- Pyridines
- Prognosis
- Neoplasm Recurrence, Local
- Mutation
- Middle Aged
- Male
- Leukemia, Myeloid, Acute
- Isocitrate Dehydrogenase
- Immunology